Intellectual property

Novartis’s Great Leap of Trust

Novartis, the $33 billion Swiss pharmaceutical company, is opening a pioneering biomedical R&D facility in China. The $100 million plant, scheduled to begin operations in May, will increase the company’s long-term access to the huge Chinese pharmaceutical market and attract top Chinese scientific talent. But CEO Daniel Vasella says there’s more to the story. Novartis, […]

by

Andrew O’Connell

by

Andrew O’Connell

From the Magazine (March 2007)

Summary.

Reprint: F0703F

CEO Daniel Vasella explains why his company is placing a big bet on China’s future as a world scientific power.

A version of this article appeared in the March 2007 issue of Harvard Business Review.

AO

Andrew O’Connell, an editor with the Harvard Business Review Group, is the author of Stats and Curiosities from Harvard Business Review.

Partner Center